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Abstract  
The hypothesis of an inflammatory component in the 
pathogenesis of atherosclerosis has been under investigation for 
a long time but the data have not been conclusive. No clinical 
trial of anti-inflammatory, anti-oxidant, or anti-bacterial agents 
has ever proven efficacious. However, the recent announcement 
and publication of the CANTOS trial has raised expectations. 
This pivotal trial showed for the first time that anti-inflammatory 
therapy targeting the interleukin-1β innate immunity pathway 
with subcutaneous injections of canakinumab every 3 months 
conferred significantly, albeit modestly (15%), lower rate of the 
composite end-point of nonfatal MI, nonfatal stroke and 
cardiovascular (CV) death than placebo, independent of lipid-
level lowering, in patients with prior myocardial infarction (MI). 
An unexpected corollary of this investigation revealed 
significant concomitant reduction in lung cancer mortality. 
Despite the initial enthusiasm about the trial results, sceptics 
point to that fact that CV mortality was not affected, while the 
incidence of fatal infections was much higher with the drug 
compared with placebo, and the cost of this therapy remains 
currently prohibitive for wider use. Ongoing and future trials 
with similar or more convenient and less expensive anti-
inflammatory agents may provide more data whether such 
results are reproducible and/or supportive or evidential of the 
inflammatory hypothesis of atherosclerosis. Rhythmos 2017; 
12(4):63-68.   
Key Words: atherosclerosis; coronary thrombosis; 
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Abbreviations: ACS = acute coronary syndrome; CAD = 
coronary artery disease; CRP = C-reactive protein; CV = 
cardiovascular; IL = interleukins; MACE = major adverse 
cardiovascular events; MI = myocardial infarction; PCI = 
percutaneous coronary intervention; RCT = randomized 
controlled trial  
INTRODUCTION 
For a long time, investigators have tried to prove that 
inflammation plays a causative role in atherosclerosis, 
however, the precise link has remained elusive.1-4 No 
clinical trial of anti-inflammatory, anti-oxidant, or anti-
bacterial agents had demonstrated efficacy in combating 
this common disease, i.e. until to date.5 The recent 
announcement and publication of the CANTOS trial 6  has 
stirred some initial enthusiasm but also skepticism.7   
CANTOS Trial 
The CANTOS trial was conducted by a team of 
investigators who had invested on the inflammatory 
hypothesis of atherosclerosis trying for a long time to 
prove their case. 3, 6, 8, 9 They randomized 10,061 patients 
(mean age 61; 90% being treated with statin) with previous 
myocardial infarction (MI) and a high-sensitivity C-
reactive protein level (hsCRP) of >2 mg/l randomized to 3 
doses of canakinumab (50 mg, 150 mg, and 300 mg, 
administered subcutaneously every 3 months), a monoclo-
nal antibody targeting interleukin-1β, and placebo. 6 The 
study was supported by the manufacturer of the antiinfla-
mmatory compound (canakinumab, Ilaris®, Novartis).  
At 48 months, the median reduction from baseline in 
the hsCRP was 26% greater in the group that received the 
50-mg dose of canakinumab, 37% greater in the 150-mg 
group, and 41% greater in the 300-mg group than in the 
placebo group. Canakinumab did not reduce lipid levels 
from baseline. At a median follow-up of 3.7 years, the 
incidence rate for the primary end point (nonfatal MI, 
nonfatal stroke, or cardiovascular – CV death) was 4.50 
events per 100 person-years in the placebo group, 4.11 
events per 100 person-years in the 50-mg group (hazard 
ratio-HR 0.93; p=0.3), 3.86 events per 100 person-years in 
the 150-mg group (HR 0.85, p=0.021), and 3.90 events per 
100 person-years in the 300-mg group (HR 0.86, p=0.031). 
The 150-mg dose, but not the other doses, met the 
prespecified multiplicity-adjusted threshold for statistical 
significance for the primary end point and the secondary 
end point that additionally included hospitalization for 
unstable angina that led to urgent revascularization (HR vs 
placebo, 0.83; P = 0.005). Canakinumab was associated 
with a higher incidence of neutropenia, thrombocytopenia 
and fatal infection and sepsis than was placebo. There was 
no significant difference in all-cause mortality. The 
authors concluded that antiinflammatory therapy targeting 
the interleukin-1β innate immunity pathway with 
canakinumab at a dose of 150 mg every 3 months led to a 
significantly lower rate of recurrent CV events than 
placebo, independent of lipid-level lowering. Interestingly, 
cancer, particularly lung cancer, mortality was 
significantly lower with canakinumab than with placebo. 
Also, canakinumab resulted in significantly fewer reports 
of arthritis, gout, and osteoarthritis than did placebo.  
In a separate publication, the benefit from canakinumab 
was shown to be limited in participants who achieved 
hsCRP concentrations <2 mg/L who had a 25% reduction 
in major adverse cardiovascular events (HR=0·75, 
p<0·0001), whereas no significant benefit was observed 
among those with on-treatment hsCRP concentrations of 
>2 mg/L (HR=0·90, p=0·11). 10    
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Critique of the CANTOS Trial 
 The accompanying editorial in the New England 
Journal of Medicine 7 points to the fact that there was no 
observed reduction of CV mortality and also to the 
worrisome increase in fatal infections. Furthermore, the 
exuberant cost of such therapy is also pointed out as this 
agent is priced at ~$200,000 per year in the US given 
monthly for approved indications (https://www.fda.gov/ 
newsevents/newsroom/pressannouncements/ucm522283.
htm). These indications comprise rare and serious auto-
inflammatory diseases in adult and pediatric patients: 
periodic fever syndrome called Cryopyrin-Associated 
Periodic Syndromes (CAPS), active systemic juvenile 
idiopathic arthritis, Tumor Necrosis Factor Receptor 
Associated Periodic Syndrome (TRAPS); Hyperimmuno-
globulin D Syndrome (HIDS)/Mevalonate Kinase Deficie-
ncy (MKD); and Familial Mediterranean Fever (FMF). 
The latter three syndromes are hereditary diseases that are 
characterized by periodic attacks of fever and 
inflammation, as well as severe muscle pain. The editorial 
mentions that an ongoing trial (CIRT) 11 is testing another 
well-known anti-inflammatory agent, low-dose 
methotrexate, in patients with diabetes or the metabolic 
syndrome and a previous MI, and concludes that “the 
modest absolute clinical benefit of canakinumab cannot 
justify its routine use in patients with previous MI until we 
understand more about the efficacy and safety trade-offs 
and unless a price restructuring and formal cost-
effectiveness evaluation supports it”.  
 In a separate article published in the Lancet, the 
CANTOS authors reported a relative risk reduction of 51% 
with the 300-mg dose, mostly driven by a 77% reduction 
in death from lung cancer. 12 Thus, some believe that the 
company may be promoting the drug more for its efficacy 
in lung cancer rather than for its CV effects!   
Enthusiasm about the use of the drug in cardiology is 
drastically tempered by the lack of effect of the drug on 
CV mortality, and also by the significant increase in fatal 
infection and sepsis, and, of course, by the exuberant cost 
of such therapy. The modest (15%) decrease in the risk for 
the composite primary end point of nonfatal MI, nonfatal 
stroke, and CV death compared with placebo, 6 although 
statistically significant (p=0.02075) and contributing to the 
inflammatory hypothesis of atherosclerosis, it remains 
doubtful whether this effect will turn out to be clinically 
significant. The results of the ongoing CIRT trial with 
methotrexate are eagerly awaited. 11   
Inflammatory Atherosclerotic Process 
Atherosclerosis has been characterized as a chronic 
inflammatory disease of the arterial vessel wall.5, 13 
Atherosclerotic lesions show features of inflammation 
akin to those found in typical inflammatory and auto 
immune disease such as rheumatoid arthritis. 14 A variety 
of cells from the vessel wall may participate in this 
inflammatory response via complex pathways.15 
Endothelial dysfunction has conventionally been 
considered the initiator of the atherosclerotic process. The 
migration and proliferation of smooth muscle cells also 
play a crucial role. In addition, the fibroblasts from the 
adventitia and adipocytes from perivascular adipose tissue 
have also been implicated in atherosclerosis. Furthermore, 
a plethora of cytokines produced by different cells from the 
arterial vessel wall, including endothelium-derived 
relaxing factors, endothelium-derived contracting factors, 
tumor necrosis factors, interleukin, adhesion molecules, 
interferon, and adventitium-derived relaxing factors, have 
been considered contributors to the pathogenesis of 
atherosclerosis.  
The inflammatory response in atherosclerosis is 
regulated by both the innate and adaptive immune system 
via the action of cytokines, a diverse group of low-
molecular weight proteins comprising the interleukins 
(IL), chemokines, colony-stimulating factors (CSF), tumor 
necrosis factors (TNF), the interferons (IFN) and 
transforming growth factors (TGF).16 Attenuating 
cytokine-induced inflammation and promoting the actions 
of anti-inflammatory cytokines represent potential 
therapeutic targets. The athero-protective effects of statins 
and certain other agents (e.g. estradiol) may be attributed 
to their pleiotropic anti-inflammatory properties. More 
specific anti-inflammatory agents, like canakinumab 
tested in the CANTOS trial,6 or methotrexate being tested 
in the Cardiovascular Inflammation Reduction Trial 
(CIRT),11 have already been proven beneficial in the 
treatment of other inflammatory disorders like rheumatoid 
arthritis, and other chronic inflammatory diseases. 
Furthermore, the protective roles of regulatory T cells 
(Tregs) and cytokines produced by them (IL-10 and TGF-
b), as well as microRNAs (miRNA) that may mitigate 
cytokine-mediated inflammation in atherosclerosis are 
actively investigated in an attempt to block pro-
inflammatory and enhance anti-inflammatory cytokine 
actions in combating atherosclerosis. In addition to IL-1β 
targeted in the CANTOS trial, other ILs, like IL-37, also a 
member of the IL-1 family, have been proposed as 
promising potential therapeutic targets in preventing or 
treating atherosclerosis. 17  IL-32 is a new cytokine, 
possibly contributing to the increased CV risk.18 A genetic 
polymorphism in IL-32 has been shown to reduce pro-
inﬂammatory cytokine production and increase HDL 
cholesterol levels, most likely reducing inﬂammation and 
lower the CV risk. 
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Inflammasomes are an integral part of the innate 
immunity, and the NLRP3 (nucleotide-binding 
oligomerization domain [NOD}, leucine-rich family 
[NLR] pyrin domain containing 3) inflammasome, also 
known as NALP3 (cryopyrin), plays an important role in 
atherosclerosis. 19-21  Activated cryopyrin, expressed 
predominantly in macrophages, detects products of 
damaged cells such as extracellular ATP and crystalline 
uric acid, and in turn triggers an immune response. 
Mutations in the NLRP3 gene are associated with a 
number of organ specific autoimmune diseases. NOD-like 
receptors (NLRs) can cooperate with Toll-like receptors 
(TLRs) and regulate inflammatory and apoptotic response.  
Inflammasomes are cytosolic protein complexes 
formed in response to offending proteins and lead to the 
production of proinflammatory enzymes such as caspase 
1, resulting in activation of proinflammatory cytokines 
such as IL-1β and IL-18 that lead to cellular apoptosis. 
Although lipid deposition in the plaque has long been 
considered a consequence of inflammation and cell death, 
activation of inflammasomes by cholesterol crystals 
provides evidence that hyperlipidemia actually promotes 
inflammation by triggering vascular wall inflammatory 
responses leading to progression of atherosclerosis.21 The 
process may be attenuated by dietary modification and 
statins’ pleiotropic effects.   
Through suppression of NLRP, compounds, such as 
resveratrol, a flavonoid that has been shown to reduce 
inflammation, moderate alcohol intake which has also 
been proposed to have a cardioprotecive effect, and the 
antidiabetic drugs, dipeptidyl dipeptidase 4 inhibitors, may 
exert their anti-inflammatory effects. Proprotein 
convertase subtilisin/kexin 9 (PCSK9) inhibitors have 
emerged as new and potent cholesterol-lowering drugs.22  
Clinical studies also suggest that PCSK9 is involved in 
atherosclerotic inflammation, while animal data indicate 
that PCSK9 gene interference could suppress 
atherosclerosis directly through decreasing vascular 
inflammation.23   
At least three major components of the inflammasome 
pathway – NLRP3, caspase 1, and IL-1β, have been 
suggested as potential therapeutic targets. Cholesterol 
crystals have been considered to incite inflammation in 
atherosclerotic plaques by stimulating the caspase-1-
activating NLRP3 inflammasome, which results in 
cleavage and secretion of IL-1β and IL-18 and finally leads 
to increased production of other inflammatory cytokines.24  
Furthermore, there is evidence that autophagy regulates 
NLRP3 inflammasome activation and has a 
atheroprotective role; on the other hand, when autophagy 
becomes dysfunctional, atherosclerotic plaque progression 
occurs.25 These findings have raised the possibility and 
guide efforts to develop novel anti-inflammatory strategies 
for prevention and treatment of atherosclerotic 
cardiovascular disease. 
Canakinumab is an IL-1β blocker. As shown in the 
CANTOS trial,6 a major concern with the development and 
use of anti-inflammatory agents or immune modulators for 
atherosclerosis relates to increased incidence of infection 
due to immune suppression; furthermore, another concern 
relates to increased incidence of malignancy, although in 
the CANTOS trial, the opposite was observed. Thus, the 
challenge remains to devise ways to target the immune 
mechanisms that produce anti-atherosclerotic effects 
without generalized immune suppression.  
Other anti-inflammatory agents have also been 
employed in CAD patients.26 In a clinical trial comprising 
532 patients with stable CAD randomized to colchicine 
(0.5 mg/d) on top of aspirin and/or clopidogrel and statins, 
the primary outcome (incidence of acute ACS, out-of-
hospital cardiac arrest, or noncardioembolic ischemic 
stroke) occurred in 15 of 282 patients (5.3%) who received 
colchicine and 40 of 250 patients (16%) assigned no 
colchicine (hazard ratio: 0.33; p < 0.001; number needed 
to treat: 11).27 The authors concluded that colchicine (0.5 
mg/day) administered in addition to statins and other 
standard secondary prevention therapies appeared 
effective for the prevention of CV events in patients with 
stable CAD.  
A phase II RCT randomized 182 patients with NSTE-
ACS, presenting <48 h from onset of chest pain to 
subcutaneous IL-1receptor antagonist (IL-1ra) or placebo 
for 14 days. 28 CRP over the first 7 days was: IL-1ra group, 
21.98 mg day/L; placebo group, 43.5 mg day/L (geometric 
mean ratio = 0.51 mg/L; P = 0.0028). In the IL-1ra group, 
14-day achieved high-sensitive C-reactive protein (P < 
0.0001) and IL-6 levels (P = 0.02) were lower than Day 1. 
Sixteen days after discontinuation of treatment (Day 30) 
high-sensitive C-reactive protein levels had risen again in 
the IL-1ra group [IL-1ra; 3.50 mg/L (2.65-4.62): placebo; 
2.21 mg/L (1.67-2.92), P = 0.022]. MACE at Day 30 and 
3 months was similar but at 1 year there was a significant 
excess of events in the IL-1ra group.  
Another potential target for anti-inflammatory 
treatment in atherosclerosis is interleukin-6 (IL-6), an 
inflammatory cytokine that plays a central role in 
propagating the downstream inflammatory response 
leading to atherosclerosis.29 IL-6 release is stimulated by 
acute infections, chronic inflammatory conditions, obesity, 
and physiologic stress. Individuals with a variant in the IL-
6 receptor that impairs classic IL-6 signaling were found 
to have a decreased risk for CAD. Tocilizumab, a 
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monoclonal antibody that targets the IL-6 receptor and 
reduces symptoms in patients with rheumatoid arthritis, 
has been shown to improve endothelial function in a high-
risk population, however it increases total cholesterol and 
LDL levels.30    
Other (Non-Inflammatory) Mechanisms of Acute 
Coronary Syndromes 
In a recent review of acute coronary syndromes (ACS), 
31 seasoned investigators point out that plaque rupture or 
erosion in ACS may occur not only in presence of 
inflammation, but also in its absence. Furthermore, ACS 
may even occur without apparent epicardial coronary 
artery thrombus or stenosis (e.g. spasm, microvascular 
disease, etc.). Thus, a more individualized approach might 
be in order for managing these syndromes, based on 
diverse pathophysiology and mechanisms, rather than an 
oversimplified general athero-thrombo-inflammatory 
strategy. Therefore, for patients with suspected active 
inflammation (e.g. high hs-CRP), anti-inflammatory 
agents might be considered; among them colchicine, the 
fully humanized anti–IL-1β monoclonal antibody, 
canakinumab, methotrexate, or even vaccines13 appear 
promising. For patients with plaque rupture without 
systemic inflammation, intensive lipid lowering treatment 
might protect against plaque destabilization, and 
sympathetic inhibition may avert plaque rupture 
triggering. In patients with arterial thrombosis caused by 
superficial erosion, pharmacological 
(anticoagulant/antiplatelet therapy) rather than 
interventional treatment may effectively manage ACS. In 
patients with ACS without plaque thrombus, nonspecific 
vasodilators such as long-acting nitrates and calcium 
channel blockers may alleviate ischemia caused by 
vasospasm. Finally, genome wide association studies in 
patients with coronary artery disease may unravel certain 
complexities of human atherosclerosis related to 
vulnerable plaque that may have therapeutic 
ramifications.32    
Inflammatory Markers 
With regards to discerning ACS patients with an active 
role of inflammation, studies have mostly used the 
determination of CRP and interleukins (ILs). Of course, 
these markers are nonspecific and other inflammatory 
diseases should be excluded before one attributes their 
elevated levels to inflammatory atherosclerosis. 
Investigational work with use of 18-fluorodeoxyglucose 
(FDG) positron emission tomography (PET) has indicated 
that there is a correlation between the intensity of 
inflammation of atherosclerotic lesions detected by FDG 
uptake and circulating inflammatory markers; hence, 
determining circulating markers of inflammation may be 
able to identify patients with unstable inflamed 
atherosclerotic plaques.33 Clinical studies indicate a good 
correlation of circulating inflammatory markers with 
proclivity to develop ischemic events and subsequent 
prognosis after ACS.4    
Vulnerable Plaque / Vulnerable Patient 
Recently a 67-year-old smoker and hyper-
cholesterolemic patient who presented with crescendo 
angina and associated inferolateral wall ischemia was 
submitted to successful percutaneous coronary 
intervention (PCI) with direct stenting of a critical lesion 
in the left circumflex coronary artery.34 However, 2 days 
later after hospital discharge he sustained new episodes of 
acute coronary syndrome with associated anterior wall 
ischemia attributed to activation of borderline lesions in 
the mid segment of the left anterior descending coronary 
artery; these were successfully remedied with implantation 
of two stents. This is an example among many whereby 
patients with CAD suffer from activation of more than one 
coronary lesions, which may not necessarily be 
angiographically critical lesions.35 This is apparently well 
explained by the presence of concurrent “active” 
inflammation of multiple vulnerable plaques which may 
rupture, a process set in motion by inflammation involved 
in the thinning of the fibrous cap, thus predisposing the 
plaque to rupture. The existence of multiple types of 
vulnerable plaques suggests that atherosclerosis is a 
diffuse inflammatory process.2  It remains a challenge to 
identify morphologic and molecular markers able to 
discriminate vulnerable plaques from stable ones, allowing 
for risk stratification and preventing measures for patients 
at high risk for acute CV events before they develop. To 
date, only high-intensity statins have proven as most 
effective approaches to stabilize atherosclerotic plaque and 
improve the cardiovascular outcome; PCSK-9 inhibitors, 
albeit much more expensive agents, are also moving in the 
same direction.36 Whether pure anti-inflammatory agents, 
as heralded by the results of the CANTOS trial, might also 
be efficacious in this regard awaits confirmation by 
ongoing and future studies.   
Conclusion and Perspective 
The CANTOS trial showed for the first time that 
antiinflammatory therapy targeting the interleukin-1β 
innate immunity pathway with subcutaneous injections of 
canakinumab every 3 months led to a significantly lower 
rate of recurrent CV events than placebo, independent of 
lipid-level lowering, in patients with prior MI. 
Interestingly, cancer, particularly lung cancer, mortality 
was significantly lower with canakinumab than with 
placebo. The announcement and concurrent publication of 
the results of this trial stirred excitement and hype about a 
67 
 
 
“wonder” new drug to combat atherosclerosis. However, 
major caveats need to be considered including the fact that 
cardiovascular mortality was not affected, the incidence of 
fatal infections was much higher with the drug compared 
with placebo, and the cost of this therapy remains currently 
prohibitive for wider use.  Importantly, the decrease in the 
risk for the composite primary end point (nonfatal MI, 
nonfatal stroke, and CV death) was only modest (15%) 
compared with placebo, and, although statistically 
significant (p=0.02075),6 it remains dubious whether this 
effect may prove to be clinically significant. Ongoing and 
future trials with similar or more convenient and less 
expensive anti-inflammatory agents may provide more 
data whether such results are reproducible and/or 
supportive or evidential of the inflammatory hypothesis of 
atherosclerosis. Finally, new emerging fields, such as 
nanotechnology and nanomedicine, may provide new 
means for advanced imaging and therapy of cardiovascular 
disease, including atherosclerosis.37    
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Table 1. Anti-inflammatory Agents with Potential 
Cardioprotective Effects 
 
Agent Mode of action Studies 
Colchicine Inhibition of 
activated neutrophils 
Nidorf et al 
Anakinra IL-1 receptor 
antagonist MRC‐ILA  Heart Study 
Inclacumab P-selectin blockade SELECT-ACS / 
SELECT-
CABG 
Atreleuton 5-lipoxygenase 
inhibitor  
VIA-ACS 
Methotrexate Decrease in IL-1, IL-
6, TNFa production 
CIRT 
Canakinumab IL-1β blockade CANTOS 
 
Table 2. Clinical Trials Examining the Role of 
Inflammation in Cardiovascular (CV) Risk 
 
 
Clinical 
Trial / 
Year 
Aim Rx Outcome 
PROVE-IT 
- TIMI 22/ 
2005 8  
To examine if 
intensive lowering of 
LDL cholesterol could 
reduce the risk of CV 
events in pts who had 
sustained an acute 
coronary syndrome  
Statins  
(atorva 
statin / 
prava 
statin) 
Reduction in both 
LDL cholesterol 
and hsCRP levels 
was predictive of a 
significant 
reduction in  
CV events 
JUPITER / 
2008 9   
To examine if hsCRP 
testing could identify 
the patients who 
remained at risk among 
those who have normal 
or low levels of LDL 
cholesterol, and, if 
statins could reduce the 
risk of heart attack and 
stroke in these patients  
Rosuva 
statin 
Benefit in pts with 
no CV disease, no 
diabetes, and 
‘acceptable’ levels 
of LDL 
cholesterol, 
suggesting that 
lowering levels of 
inflammation may 
reduce CV events  
IMPROVE
-IT / 2015 38   
To examine the role of 
dual targets by 
lowering both LDL 
cholesterol and hsCRP  
Simva 
statin or 
ezetimibe
/simva 
statin 
LDL cholesterol 
and hsCRP 
lowering was 
associated with 
improved CV 
outcomes 
CANTOS / 
2017 6   
To examine the role of 
anti-inflammatory 
treatment on CV risk 
Canakinu
mab 
Reduced CV risk 
in pts with a prior 
MI 
 
CV = cardiovascular; hsCRP = high-sensitivity C=reactive 
protein; LDL = low-density lipoprotein; MI = myocardial 
infarction; pts = patients; Rx = treatment   
